Table 2 Summary of treatments in the MP group and DXM group
Treatments | MP group (n = 25) | DXM group (n = 25) | p-value |
|---|---|---|---|
Antiviral | |||
Favipiravir only | 5 (20%) | 10 (40%) | |
Remdesivir only | 12 (48%) | 11 (44%) | |
Both favipiravir and remdesivir | 7 (28%) | 4 (16%) | |
Monupiravir only | 1 (4%) | 0 (0%) | 0.325 |
Extended steroids (> 10 days) | 3 (12%) | 3 (12%) | 1.000 |
Anticoagulant | 12 (48%) | 9 (36%) | 0.390 |
Immunomodulators | |||
None | 22 (88%) | 22 (88%) | |
Tocilizumab | 1 (4%) | 1 (4%) | |
Baricitinib | 2 (8%) | 2 (8%) | 1.000 |